These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 24561246)

  • 1. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
    Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
    Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
    Park JY; Lee SH; Seong SJ; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
    Gynecol Oncol; 2013 Apr; 129(1):7-11. PubMed ID: 23283299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer.
    Tamauchi S; Nakagawa A; Yoshida K; Yoshihara M; Yokoi A; Yoshikawa N; Niimi K; Kajiyama H
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1614-1621. PubMed ID: 39092804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer.
    Park JY; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
    Obstet Gynecol; 2013 Jan; 121(1):136-42. PubMed ID: 23262938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued medical treatment for persistent early endometrial cancer in young women.
    Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
    Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
    Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
    Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
    Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
    Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
    Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
    Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
    Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
    Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.